BRIEF published on 07/23/2025 at 12:55, 10 months 4 days ago Waldencast Acquires Novaestiq Corp. from Gore Range Capital Acquisition FDA Approval Injectable Gel Obagi Medical Waldencast
BRIEF published on 07/23/2025 at 12:55, 10 months 4 days ago Waldencast acquiert Novaestiq Corp. auprès de Gore Range Capital Acquisition Approbation De La FDA Obagi Medical Waldencast Gel Injectable
PRESS RELEASE published on 07/23/2025 at 12:50, 10 months 4 days ago Gore Range Capital Announces Sale of Novaestiq Corp. to Waldencast Waldencast to acquire Novaestiq Corp. under Obagi Medical, strengthening portfolio with injectable hyaluronic acid gels for US market. Saypha® products set to redefine skincare experience Obagi Medical Waldencast Novaestiq Corp. Saypha® Injectable Hyaluronic Acid Gels
Published on 05/28/2026 at 01:15, 6 hours 29 minutes ago JM Capital II Corp. Announces Departure of President, Chief Financial Officer and Chief Financial Officer Jay Freeman
Published on 05/28/2026 at 00:55, 6 hours 49 minutes ago First Helium Closes Oversubscribed $2.6 Million Placement
Published on 05/27/2026 at 23:42, 8 hours 2 minutes ago New Horizon Aircraft Ltd. Announces Closing of $25 Million Offering of Common Shares
Published on 05/27/2026 at 23:05, 8 hours 39 minutes ago Vox Royalty Announces Annual and Special Meeting Results
Published on 05/27/2026 at 23:05, 8 hours 39 minutes ago Avino Reports Voting Results of Its 2026 Annual General Meeting
Published on 05/28/2026 at 07:30, 14 minutes ago EVN AG: Business development in the first half of 2025/26
Published on 05/28/2026 at 07:30, 14 minutes ago Ernst Russ AG Publishes Business Figures for the First Quarter of 2026
Published on 05/28/2026 at 07:30, 14 minutes ago Northern Data Group Announces CFO Move to Advisory Role
Published on 05/28/2026 at 07:30, 14 minutes ago Magirus starts 2026 with strong momentum in Q1, record high order intake; Mutares initiates preparation of exit process
Published on 05/28/2026 at 07:30, 14 minutes ago BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance
Published on 05/27/2026 at 23:00, 8 hours 44 minutes ago BIOPHYTIS MODIFIE SA LIGNE DE FINANCEMENT AVEC HEXAGON CAPITAL FUND POUR RENDRE RENOUVELABLE SA CAPACITE DE TIRAGE DE 2M€
Published on 05/27/2026 at 23:00, 8 hours 44 minutes ago BIOPHYTIS CHANGES ITS FINANCING AGREEMENT WITH HEXAGON CAPITAL FUND TO ENSURE ITS €2 MILLION FACILITY IS RENEWABLE
Published on 05/27/2026 at 20:28, 11 hours 15 minutes ago Combined Shareholders’ Meeting of May 27, 2026
Published on 05/27/2026 at 17:45, 13 hours 59 minutes ago Imerys-05-2026-communique-capital-droits-de-vote-au-30-avril-2026
